Kit Simpson to Pyridines
This is a "connection" page, showing publications Kit Simpson has written about Pyridines.
Connection Strength
1.378
-
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-na?ve and -experienced United Kingdom patients in 2011. J Med Econ. 2012; 15(4):796-806.
Score: 0.351
-
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
Score: 0.279
-
Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
Score: 0.267
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
Score: 0.241
-
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
Score: 0.241